

RE: Pharmacokinetic data demonstrating that REYATAZ (atazanavir sulphate) combined with NORVIR (ritonavir) and omperazole should not be co-administered

Following presentation of pharmacokinetic data on the co-administration of REYATAZ (atazanavir sulphate), NORVIR (ritonavir) and omperazole at a meeting of the Committee for Human Medicinal Products (CHMP). The Medicines Authority (MA) is of the opinion that the advice provided by the CHMP for the co-administration of REYATAZ (atazanavir sulphate) combined with NORVIR (ritonavir) and omperazole is opportune and appropriate. You are kindly requested to note the recommendations which the CHMP has made in the press release issued by the European Medicines Agency to prescribers and patients regarding the co-administration of atazanavir, ritonavir and omperazole.